Twist Bioscience Corporation reported record total revenue of $376.6 million for fiscal year 2025, a 20% increase from $313.0 million in fiscal year 2024. Fourth quarter revenue reached $99.0 million, up 17% from $84.7 million in the same quarter last year, marking the company's 11th consecutive quarter of sequential growth. SynBio revenue for fiscal 2025 was $145.0 million, representing a 17% increase from $123.5 million in fiscal 2024. Gross margin improved to 50.7% in fiscal 2025, up from 42.6% the previous year. The company appointed Trynka Shineman to its board of directors. For fiscal 2026, Twist Bioscience expects total revenue between $425 million and $435 million, with DNA Synthesis and Protein Solutions revenue projected at $194 million to $199 million and NGS Applications revenue at $231 million to $236 million. Gross margin is expected to exceed 52%, and the company anticipates achieving adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.